RU2014111179A - CONJUGATES OF INTERFERON λ1 AND POLYETHYLENE GLYCOL - Google Patents
CONJUGATES OF INTERFERON λ1 AND POLYETHYLENE GLYCOL Download PDFInfo
- Publication number
- RU2014111179A RU2014111179A RU2014111179/10A RU2014111179A RU2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179/10 A RU2014111179/10 A RU 2014111179/10A RU 2014111179 A RU2014111179 A RU 2014111179A RU 2014111179 A RU2014111179 A RU 2014111179A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- conjugate
- polyethylene glycol
- conjugate according
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Abstract
1. Физиологически активный конъюгат полиэтиленгликоля и интерферона λ1, имеющий формулу I:где R представляет собой Н или Cалкил;m равно 1, 2, 3 или 4;n - положительное целое число, выбранное диапазона от 400 до 550 или от 900 до 945;L представляет собой Cалкильный или гетероалкильный линкер;X представляет собой -O-, -NH- или -S-; иIFNλ1 означает интерферон λ1;или его фармацевтически приемлемая соль.2. Конъюгат по п. 1, в котором R представляет собой H или -CH, m равно 1, L представляет собой -C(O)-, а X представляет собой -NH-.3. Конъюгат по п. 1 или 2, в котором n равно от 500 до 550 или от 900 до 945.4. Конъюгат по п. 1, соответствующий формуле:где INFλ1 - интерферон λ1, имеющий последовательность SEQ ID 2; а n равно от 500 до 550 или от 900 до 945.5. Конъюгат по любому из пп. 1, 2 и 4, характеризующийся временем полужизни и удержанием в сыворотке крови, превышающими соответствующие значения для интерферона λ1.6. Конъюгат по любому из пп. 1, 2 и 4, в котором полиэтиленгликоль присоединен к метионину на N-конце интерферона λ1.7. Фармацевтическая композиция, содержащая конъюгат по любому из пп. 1-6, фармацевтически приемлемые носители и эксципиенты.8. Фармацевтическая композиция по п. 7, предназначенная для лечения гепатита В и гепатита С.9. Способ получения человеческого рекомбинантного конъюгата, соответствующего п. 1, включающий стадию ковалентного связывания (α-метокси-ω-(4-нитрофеноксикарбонил))полиоксиэтилена (PEG-pNC) с молекулярной массой 40 кДа с интерфероном λ1 в результате изображенной ниже реакции конъюгации:где n - положительное целое число, выбираемое из диапазона 900-945, так чтобы молекулярная масса полиэтиленгликольного остатка составляла около 40 кДа; и выделение указанного конъюгата.10. 1. The physiologically active conjugate of polyethylene glycol and interferon λ1, having the formula I: where R represents H or C 1-6 alkyl; m is 1, 2, 3 or 4; n is a positive integer selected in the range from 400 to 550 or from 900 to 945; L represents a C 1-6 alkyl or heteroalkyl linker; X represents —O—, —NH— or —S—; and IFNλ1 is interferon λ1; or a pharmaceutically acceptable salt thereof. 2. The conjugate of claim 1, wherein R is H or —CH, m is 1, L is —C (O) -, and X is —NH — .3. The conjugate according to claim 1 or 2, in which n is from 500 to 550 or from 900 to 945.4. The conjugate according to claim 1, corresponding to the formula: where INFλ1 is interferon λ1 having the sequence of SEQ ID 2; and n is from 500 to 550 or from 900 to 945.5. The conjugate according to any one of paragraphs. 1, 2 and 4, characterized by a half-life and retention in serum exceeding the corresponding values for interferon λ1.6. The conjugate according to any one of paragraphs. 1, 2 and 4, in which polyethylene glycol is attached to methionine at the N-terminus of interferon λ1.7. A pharmaceutical composition comprising a conjugate according to any one of claims. 1-6, pharmaceutically acceptable carriers and excipients. 8. The pharmaceutical composition according to claim 7, intended for the treatment of hepatitis B and hepatitis C.9. A method for producing a human recombinant conjugate according to claim 1, comprising the step of covalently linking (α-methoxy-ω- (4-nitrophenoxycarbonyl)) polyoxyethylene (PEG-pNC) with a molecular weight of 40 kDa with interferon λ1 as a result of the conjugation reaction shown below: where n is a positive integer selected from the range of 900-945, so that the molecular weight of the polyethylene glycol residue is about 40 kDa; and isolating said conjugate. 10.
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
VN201102222 | 2011-08-25 | ||
VNVN1-2011-02222 | 2011-08-25 | ||
PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014111179A true RU2014111179A (en) | 2015-09-27 |
Family
ID=47746747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014111179/10A RU2014111179A (en) | 2011-08-25 | 2012-03-01 | CONJUGATES OF INTERFERON λ1 AND POLYETHYLENE GLYCOL |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2748328A4 (en) |
JP (1) | JP2014525939A (en) |
CN (1) | CN103228792A (en) |
AU (1) | AU2012299423A1 (en) |
BR (1) | BR112014004302A2 (en) |
CA (1) | CA2846092A1 (en) |
RU (1) | RU2014111179A (en) |
WO (1) | WO2013028233A1 (en) |
ZA (1) | ZA201401159B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883156A (en) | 2016-02-19 | 2018-11-23 | 艾格尔峰生物制药有限公司 | Hepatitis delta viral infection is treated with interferon lambda |
EP3375452A1 (en) | 2017-03-16 | 2018-09-19 | Evangelos Andreakos | Use of lambda interferons in the treatment of disorders and related diseases |
RU2678332C1 (en) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof |
CN112245570A (en) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | Interferon-based disease treatment method |
CA3206014A1 (en) | 2021-01-21 | 2022-07-28 | Lu Zhuang | Interferon-based cancer treatment method, and pharmaceutical combination |
WO2022156733A1 (en) | 2021-01-21 | 2022-07-28 | 厦门特宝生物工程股份有限公司 | Method and pharmaceutical combination for preventing cancer recurrence |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
CN1176137C (en) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine |
CN1927388B (en) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | Medicinal composition containing human interferon |
WO2006133089A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
PL1931704T3 (en) * | 2005-10-04 | 2011-06-30 | Zymogenetics L L C | Production and purification of il-29 |
CN101002942B (en) * | 2007-01-08 | 2010-07-21 | 湖南大学 | PEG type elaioplast nanometer particle |
CN103536906A (en) * | 2008-06-05 | 2014-01-29 | 津莫吉尼蒂克斯公司 | Use of pegylated Type III Interferons for the treatment of hepatitis C |
-
2012
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en unknown
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/en active Pending
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/en not_active Application Discontinuation
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/en not_active IP Right Cessation
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/en not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201401159B (en) | 2015-04-29 |
CN103228792A (en) | 2013-07-31 |
EP2748328A4 (en) | 2015-03-04 |
BR112014004302A2 (en) | 2017-06-20 |
EP2748328A1 (en) | 2014-07-02 |
JP2014525939A (en) | 2014-10-02 |
AU2012299423A1 (en) | 2014-03-06 |
CA2846092A1 (en) | 2013-02-28 |
WO2013028233A1 (en) | 2013-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014111179A (en) | CONJUGATES OF INTERFERON λ1 AND POLYETHYLENE GLYCOL | |
RU2008126305A (en) | NEW PEPTID | |
US20200061165A1 (en) | Methods and compositions for modulating the immune system with arginase i | |
CN109467566B (en) | Bis-diazabicyclo compounds for use in the treatment and/or prevention of diseases or disorders associated with hepatitis virus | |
JP2011522834A5 (en) | ||
JP2010518079A5 (en) | ||
US8454947B1 (en) | PEG-interferon lambda 1 conjugates | |
KR102599942B1 (en) | Combination therapy of hbv and hdv infection | |
JP2014525939A5 (en) | ||
RU2010144014A (en) | APPLICATION OF PEGILIATED IGF-I OPTIONS FOR TREATMENT OF NEUROMUSCULAR DISORDERS | |
RU2013148779A (en) | TREATMENT OF HEPATITIS VIRUS INFECTION IN SEPARATELY OR IN COMBINATION WITH DELTA HEPATITIS VIRUS AND LIVER-LIVING DISEASES OF THE LIVER | |
RU2010126598A (en) | APPLICATION OF A HUMAN ANTIBODY ABLE TO NEUTRALIZE HEPATITIS B VIRUS FOR PREVENTION OR TREATMENT OF HEPATITIS B VIRUS INFECTION | |
US20150202218A1 (en) | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections | |
US7985734B2 (en) | Peptides for preventing or treating liver damage | |
RU2011131872A (en) | APL APPLICATION PEPTIDE FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASE AND TYPE 1 DIABETES | |
EP3191504A1 (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
MX2008014358A (en) | Polyethylene glycol-interferon alpha conjugate. | |
RU2006101166A (en) | RECOMBINANT ANTIBODIES AND COMPOSITIONS AND METHODS FOR PRODUCING AND USING THEM | |
RU2008125167A (en) | THERAPEUTIC FOR ACCELERATED HEALING OF SKIN CONTAINING AS AN ACTIVE INGREDIENT OF DESACYL-GRELIN AND ITS DERIVATIVES | |
JP2006524704A (en) | Treatment or prevention of respiratory viral infections with alpha thymosin peptides | |
TW201010692A (en) | Pharmaceutical composition for treatment or prevention of hbv infection | |
RU2597795C2 (en) | Inhibitor of liquid in cavities of body accumulation | |
WO2016085279A2 (en) | Cell penetrating peptide-immunomodulator conjugate and composition, containing same, for treating immune diseases | |
CN1264308A (en) | Medicinal compositions for treating immunodeficinecy diseases | |
JP2015509980A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160914 |